Free Trial

HilleVax (HLVX) Stock Price, News & Analysis

+0.52 (+3.58%)
(As of 10:52 AM ET)
Today's Range
50-Day Range
52-Week Range
117,324 shs
Average Volume
141,372 shs
Market Capitalization
$748.29 million
P/E Ratio
Dividend Yield
Price Target

HilleVax MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
96.6% Upside
$29.00 Price Target
Short Interest
3.29% of Float Sold Short
Dividend Strength
News Sentiment
0.51mentions of HilleVax in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$985.94 M Sold Last Quarter
Proj. Earnings Growth
From ($3.14) to ($3.01) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.26 out of 5 stars

Medical Sector

313th out of 921 stocks

Biological Products, Except Diagnostic Industry

40th out of 150 stocks

HLVX stock logo

About HilleVax Stock (NASDAQ:HLVX)

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

HLVX Stock Price History

HLVX Stock News Headlines

HilleVax (NASDAQ:HLVX) Price Target Raised to $24.00
HilleVax (NASDAQ:HLVX) Given "Buy" Rating at HC Wainwright
Recap: HilleVax Q4 Earnings
Aditya Kohli's Net Worth
HilleVax Appoints GSK's Sean McLoughlin As COO
See More Headlines
Receive HLVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HilleVax and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$5.48 per share


Free Float
Market Cap
$722.43 million
Not Optionable
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

HLVX Stock Analysis - Frequently Asked Questions

Should I buy or sell HilleVax stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HilleVax in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HLVX shares.
View HLVX analyst ratings
or view top-rated stocks.

What is HilleVax's stock price target for 2024?

4 Wall Street analysts have issued twelve-month price objectives for HilleVax's stock. Their HLVX share price targets range from $24.00 to $34.00. On average, they expect the company's stock price to reach $29.00 in the next year. This suggests a possible upside of 96.6% from the stock's current price.
View analysts price targets for HLVX
or view top-rated stocks among Wall Street analysts.

How have HLVX shares performed in 2024?

HilleVax's stock was trading at $16.05 on January 1st, 2024. Since then, HLVX shares have decreased by 8.1% and is now trading at $14.75.
View the best growth stocks for 2024 here

When is HilleVax's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our HLVX earnings forecast

How were HilleVax's earnings last quarter?

HilleVax, Inc. (NASDAQ:HLVX) issued its quarterly earnings results on Wednesday, March, 20th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.80) by $0.02.

What ETFs hold HilleVax's stock?

ETFs with the largest weight of HilleVax (NASDAQ:HLVX) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM).Morningstar US Small Growth (MSGR).

When did HilleVax IPO?

HilleVax (HLVX) raised $200 million in an IPO on Friday, April 29th 2022. The company issued 11,765,000 shares at $16.00-$18.00 per share.

Who are HilleVax's major shareholders?

HilleVax's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.74%), California State Teachers Retirement System (0.04%), Tidal Investments LLC (0.03%), SG Americas Securities LLC (0.02%) and EntryPoint Capital LLC (0.01%). Insiders that own company stock include Aditya Kohli, Astrid Borkowski, Life Sciences X LP Frazier, Robert Hershberg, Sean Mcloughlin and Shane Maltbie.
View institutional ownership trends

How do I buy shares of HilleVax?

Shares of HLVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HLVX) was last updated on 5/22/2024 by Staff

From Our Partners